<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002270</url>
  </required_header>
  <id_info>
    <org_study_id>JAB-21822-1001</org_study_id>
    <nct_id>NCT05002270</nct_id>
  </id_info>
  <brief_title>JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation</brief_title>
  <official_title>A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacobio Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jacobio Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and&#xD;
      combination therapy in adult participants with advanced solid tumors harboring KRAS G12C&#xD;
      mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of JAB-21822&#xD;
      monotherapy to determine the MTD and PR2D during Dose Escalation phase; then to evaluate&#xD;
      preliminary antitumor activity when JAB-21822 administered alone and combination with&#xD;
      cetuximab during Dose Expansion phase in adult participants with advanced solid tumors&#xD;
      harboring KRAS G12C mutation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Escalation and Dose Expansion phase: Number of participants with adverse events</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Patients will be assessed for incidence and severity of adverse events (AEs) according to NCI-CTCAE criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion phase: Overall response rate (ORR)</measure>
    <time_frame>Up to 4 years - from baseline to RECIST confirmed Progressive Disease</time_frame>
    <description>ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) per RECIST v 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion phase: Duration of response ( DOR )</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>DOR is defined as the time from the participant's initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Dose Expansion phase: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Cmax of JAB-21822 alone or JAB-21822 plus cetuximabn will be measured by using plasma PK samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Dose Expansion phase: Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>AUC of JAB-21822 alone or JAB-21822 plus cetuximab will be measured by using plasma PK samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation phase: Overall response rate (ORR)</measure>
    <time_frame>Up to 4 years - from baseline to RECIST confirmed Progressive Disease</time_frame>
    <description>The percentage of participants with complete response (CR) or partial response (PR) on RECIST v 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation phase: Duration of response ( DOR )</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>DOR is defined as the time from the participant's initial objective response (CR or PR) to disease progression per CTCAE v1.1 or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Dose Expansion phase: Disease Control Rate ( DCR )</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>DCR is defined as percentage of participants with complete response (CR), partial response (PR), or stable disease(SD) per CTCAE v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation and Dose Expansion phase: Progression-free survival (PFS)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression per CTCAE v1.1 or death which occurs first</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>NSCLC</condition>
  <condition>CRC</condition>
  <arm_group>
    <arm_group_label>Arm A0, JAB-21822 monotherapy, Phase 1, Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of JAB-21822 will be administered alone to determine the MTD and RP2D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A1, JAB-21822 monotherapy, Phare 2, Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JAB-21822 will be administered alone at RP2D in selected cancer type patients to evaluate the preliminary antitumor activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Arm B, JAB-21822 combination with Cetuximab, Phase 2, Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JAB-21822 will be administered together with Cetuximab in mCRC patients to evaluate the preliminary antitumor activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAB-21822 (KRAS G12C inhibitor)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Arm A0, JAB-21822 monotherapy, Phase 1, Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAB-21822 (KRAS G12C inhibitor)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Arm A1, JAB-21822 monotherapy, Phare 2, Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAB-21822 (KRAS G12C inhibitor)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Experimental: Arm B, JAB-21822 combination with Cetuximab, Phase 2, Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab (EGFR inhibitor)</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Experimental: Arm B, JAB-21822 combination with Cetuximab, Phase 2, Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be able to provide an archived tumor sample&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumors with KRAS G12C mutation&#xD;
&#xD;
          -  Must have received at least 1 prior standard therapy&#xD;
&#xD;
          -  Must have at least 1 measurable lesion per RECIST v1.1&#xD;
&#xD;
          -  Must have adequate organ function&#xD;
&#xD;
          -  Must be able to swallow and retain orally administered medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has brain or spinal metastases, except if treated and no evidence of radiographic&#xD;
             progression or hemorrhage for at least 28 days&#xD;
&#xD;
          -  Active infection requiring systemic treatment within 7 days&#xD;
&#xD;
          -  Active HBV or HCV&#xD;
&#xD;
          -  Any severe and/or uncontrolled medical conditions&#xD;
&#xD;
          -  LVEF â‰¤50% assessed by ECHO or QTcF&#xD;
&#xD;
          -  QT interval &gt;470 msec&#xD;
&#xD;
          -  Experiencing unresolved CTCAE 5.0 Grade &gt;1 toxicities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huiqiang Wang, PhD</last_name>
    <phone>86 10 56315466</phone>
    <email>Huiqiang.wang@jacobiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ramina Mikailova</last_name>
    <email>ramina.mikailova@jacobiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinc</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinc</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS G12C Mutant Advanced Solid Tumor; NSCLC; CRC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

